Recent events
Recent events tied to this brand in public sources.
Back to profile12 entries
2022
Radient completes acquisition of Tunaaaaroom Xtracts
Radient Technologies completed its acquisition of all issued and outstanding securities of Alberta cannabis company Tunaaaaroom Xtracts. The acquisition remained subject to final approval by the TSX Venture Exchange.
2022
Radient director Yves Gougoux resigns
Yves Gougoux resigned as a director of Radient Technologies effective January 28, 2022.
2022
Radient and All Good partner on cannabis pre-roll production
Radient announced a partnership agreement with All Good to produce cannabis pre-roll products. Under the agreement, Radient entered an agreement with All Good to design and supply a modular assembly and packaging facility at Radient's Edmonton II plant.
2021
Radient agrees to acquire Tunaaaaroom Xtracts
Radient announced a definitive agreement to acquire Tunaaaaroom Xtracts Inc. in an all-stock transaction. The proposed acquisition was expected to close before December 31, 2021, subject to customary closing conditions including TSX Venture Exchange approval.
2021
Radient guides to 2021 revenue of at least $20–$25 million
Radient management said it believed gross revenues would be in the $20–$25 million range at a minimum for calendar 2021.
2020
Radient Technologies signs licensing agreement with Tunaaaa
Radient Technologies announced a licensing agreement with Tunaaaa to manufacture and distribute premium cannabis extracts in Canada. The agreement gives Radient access to Tunaaaa's genetics and engages Tunaaaa breeders as product-development consultants.
2020
Radient enters licensing agreement for Dreamy CBD brands
Radient announced a licensing agreement with Dreamy Co. granting Radient exclusive rights to licenses and trademarks for Dreamy CBD brands. The parties plan to launch the brands in Canada, and Radient is to produce CBD products for Thailand and Japan after reviewing local trade requirements.
2020
Radient Technologies reports first-quarter fiscal 2021 results
Radient Technologies announced its results for the first quarter ended June 30, 2020. It reported quarterly revenue of $42,435 and a net loss of $5,431,086.
2020
Radient products to be included in Shoppers medical cannabis study
Radient announced that its bioU products would be available to patients in the University Health Network's Medical Cannabis Real-World Evidence Study, conducted in partnership with Medical Cannabis by Shoppers. The study is described as a nationwide clinical trial examining medical cannabis effects on pain, sleep, and anxiety.
2020
Radient enters manufacturing and service agreement with Premium 5
Radient announced a renewable one-year manufacturing and service agreement with Premium 5 covering multiple products under Premium 5's brand. Radient will supply distillate and provide manufacturing services for at least 240,000 units.
2020
Radient receives Canadian sales license amendment for cannabis extracts, edibles and topicals
Radient Technologies received a Health Canada license amendment authorizing sales of cannabis extracts, edibles and topicals.
2020
Radient announces collaboration to develop antiviral products
Radient announced that it would lead a collaboration with IntuitiveX and ipCapital to explore developing antiviral products using cannabinoid-based formulations. The announcement described product development as a goal; it did not report that products had been developed or that patient studies had been scheduled.